The FDA has approved Shionogi's Xocova (ensitrelvir) for post-exposure prevention of Covid-19 in adults and adolescents aged ...

The U.S. FDA has approved ensitrelvir (Xocova), an oral antiviral developed by Shionogi, to help prevent COVID-19 in ...

Sneezing in the morning, a runny nose or coughing often goes unnoticed as minor ailments in kids. However, these harmless ...

The FDA on Monday approved the first medication for COVID-19 prevention that people can take after they have been exposed to ...

In a major expansion of the pandemic treatment toolkit, the U.S. Food and Drug Administration (FDA) has officially approved ...

The FDA recently approved ensitrelvir (Xocova; Shionogi), an anti–SARS-CoV-2 oral drug for post-exposure prophylaxis (PEP) of COVID-19, for adults and adolescents 12 years of age and older. 1 The ...

Two-thirds of people with post-COVID-19 syndrome have persistent, objective symptoms – including reduced physical exercise capacity and reduced cognitive test performances – for a year or more, with ...

Persistent radiologic abnormalities after COVID-19 were common 28-60 days post-discharge, often showing improvement but remaining linked to long-term health quality, highlighting a population ...

Doctors report rising hip replacements among young Indians post-COVID, linking steroid use and avascular necrosis to severe ...

FDA approves Shionogi’s Xocova as First Oral Post-Exposure Covid-19 Prevention Therapy, marking a major milestone for Covid-19 prevention treatments. FDA has approved Shionogi’s Xocova (ensitrelvir) ...